October 7th , 2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer